Background: To date, general anesthesia has been suggested as the preferred approach for implantation of a subcutaneous implantable cardioverter-defibrillator (S-ICD). The purpose of this study was to assess the use of monitored anesthesia care (MAC) for S-ICD implantation. The goals were to assess adequate sedation and analgesia (efficacy endpoints) and major perioperative airway or hemodynamic compromise (safety endpoints). The authors hypothesized that MAC may provide adequate sedation and analgesia and no major perioperative airway or hemodynamic compromise during S-ICD implantation and multiple defibrillation threshold (DFT) testing.
T HE SUBCUTANEOUS IMPLANTABLE cardioverterdefibrillator (S-ICD) system is composed of a pulse generator and a single subcutaneous electrode, and was developed as a substitute for conventional transvenous ICD systems. [1] [2] [3] It has demonstrated efficacy and safety in the management of malignant ventricular arrhythmias, and currently is being implanted globally at an accelerated rate. [1] [2] [3] [4] [5] The two largest clinical trials, the S-ICD IDE study and the EFFORTLESS study, involved the use of general anesthesia (GA), 3, 4 and most anesthesiologists consider GA the preferred method for S-ICD implantation due to the extensive dissection and tunneling, multiple defibrillation threshold (DFT) testing of induced ventricular fibrillation (VF), and attendant cardiovascular depression associated with DFT testing. 6 However, a recent study reported significant reductions in blood pressure and heart rate (HR), requiring pharmacotherapy, and related to GA during S-ICD implantation and DFT testing. 6 Monitored anesthesia care (MAC) may avert these hemodynamic changes. 7 The purpose of this study, therefore, was to describe outcomes when using MAC during S-ICD implantation. The hypothesis of this study was that MAC would provide adequate sedation and analgesia (efficacy endpoints) and no major perioperative airway or hemodynamic compromise (safety endpoints) during S-ICD implantation and DFT testing.
MATERIALS AND METHODS

Study Design
This was a single-center, non-randomized descriptive study of outcomes in 10 patients undergoing S-ICD implantation for Class I or II indications with MAC at The Ohio State University Wexner Medical Center between January 2015 and January 2016. Patients were identified through a retrospective analysis of prospective S-ICD database. The study was approved by the local institutional review board.
Outcome Measures
The efficacy endpoints consisted of the following: (1) the provision of an optimal depth of sedation and analgesia to facilitate S-ICD implantation without intra-procedure patient discomfort or awareness; and (2) the absence of "severe" pain at the lead tunneling and generator insertion sites postprocedure. 8 The safety endpoints included: (1) periprocedural hypotension, as defined by a mean arterial pressure (MAP) o 60 mmHg refractory to conventional doses of inotropic or vasopressor support, (2) HR o 45 bpm requiring chronotropic therapy, and (3) sedation-induced airway compromise requiring endotracheal intubation. [8] [9] [10] Pre-Procedure All S-ICD implantations were performed under the guidance of a cardiovascular anesthesiologist per institutional protocol. The decision to use MAC for S-ICD implantation was made in the electrophysiology laboratory pre-procedure holding area after consultation with the implanting electrophysiologist and following evaluation of the patient. The main considerations in selecting MAC were to avoid potential airway compromise, aspiration, and cardiovascular collapse. 8, 10, 11 A myriad of factors were considered in the decision-making process, as per the American Society of Anesthesiologists (ASA) recommendations for MAC, inclusive of but not limited to: distorted head and neck anatomy predictive of intubation difficulty, history of difficult intubation, poorly controlled gastroesophageal reflux disease, obesity, history of obstructive sleep apnea, history of moderate-to-severe pulmonary hypertension, baseline hemodynamics, and the inability to have direct access to the patient's airway during the procedure. 10,11 Patients with the aforementioned conditions were considered poor candidates for MAC, and subsequently underwent S-ICD implantation under GA. Furthermore, the majority of outpatient cardiovascular medications were continued in the perioperative period in order to avoid potential exacerbation of baseline cardiac disease. Continued medications were inclusive of beta-blockers, aspirin, diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blocking agents ( Table 1) .
Intra-Procedure S-ICD system implantation procedures were performed in an electrophysiology laboratory equipped with anesthesia equipment. All monitoring was completed noninvasively. After appropriate patient positioning, supine with the left arm extended away from the body, continuous monitoring was initiated with pulse oximetry, capnography, and electrocardiography. 11 Noninvasive blood pressure measurements, respiratory rate, and hemodynamic variables were recorded electronically at least every 5 minutes. Supplemental oxygen was administrated using a MAC-safe nasal cannula or a simple facemask with a capnography attachment. The baseline MAP and HR, recorded prior to the initiation of sedation, were compared to the lowest intra-procedure value and the final intra-procedure value for each patient.
Propofol infusion was used in all patients, with a mean minimum infusion rate of 42 Ϯ 13.08 μg/kg/min and a mean maximum infusion rate of 107.50 Ϯ 42.09 μg/kg/min. The propofol infusion was supplemented with other sedatives and/ or analgesics in a limited number of patients. Five patients received midazolam (mean dose of 3.60 Ϯ 2.33 mg), four patients received fentanyl (mean dose of 87.50 Ϯ 21.65 μg), and two patients received ketamine (mean dose of 50 Ϯ 0 mg). At the pulse generator insertion site and at the inferior margin of the xiphoid process, the electrophysiologists injected 1% lidocaine subcutaneously for analgesia.
The S-ICD implantation procedure is well described. 6,12 In summary, a pulse generator (A209 EMBLEM model, Boston Scientific, Marlborough, MA) is implanted in a subcutaneous pocket created at the level of the sixth intercostal space along the left anterior-axillary line. Considering that the pulse generator pocket was created after the infiltration of local anesthesia, this period required mild-to-moderate sedation in the study patients. A S-ICD electrode (Q-TRAK, Boston Scientific, Marlborough, MA) was then implanted subcutaneously from the pulse generator MONITORED ANESTHESIA FOR S-ICD IMPLANTATION pocket medially to the inferior margin of the xiphoid process and further tunneled cranially along the left parasternal border towards the sternal notch. 6 In this study, tunneling of the defibrillator lead required deep sedation due to the inability to infiltrate local anesthesia along the entire path of the lead. Defibrillation testing was performed at the discretion of the electrophysiologist and was completed in seven patients with deep sedation to prevent awareness. Through the S-ICD, VF was induced and then S-ICD performance, detection and successful defibrillation of VF, were monitored. If the S-ICD shock therapy was unsuccessful in restoring sinus rhythm, the patient was rescued with a transcutaneous biphasic shock Z 300 J. In the event a patient experienced hypotension during DFT testing, incremental doses of inotropic/vasopressor agents with phenylephrine, epinephrine, or ephedrine were administered at the discretion of the anesthesiologist. Defibrillation threshold testing was not performed in three patients due to limitations identified by the electrophysiologist.
The propofol infusion was discontinued at the end of the procedure, and the patients were thereafter transferred to the post-anesthesia care unit after the full return of consciousness.
Post-Procedure
In the post-anesthesia care unit, the following parameters were monitored: vital signs, oximetry, telemetry, and pain scores. Incisional pain at the lead tunneling site and the S-ICD generator insertion site was graded by the patient using a 4point verbal pain scale as "none," "mild," "moderate," or "severe." Intravenous hydromorphone was the drug of choice for postoperative pain control.
Statistical Analysis
SAS Statistical Software Version 9.4 (SAS Institute, Inc., Cary, NC) was used for data analysis. Continuous variables were summarized as mean Ϯ standard deviation, and categorical variables as frequency and percentage. Continuous variables were compared using a Student's t-test for paired samples. Categorical variables were compared using a Chi-Square Analysis.
RESULTS
Patient Population Demographics and Baseline Characteristics
Between January 2015 and January 2016, 35 patients underwent S-ICD implantation at the authors' institution, 10 of which were performed with MAC ( Table 1 ). The 10 study patients had a mean age of 55.90 Ϯ 16.13 years, and were equally represented with respect to sex (50% males and 50% females). The majority of the patients had an ASA classification of IV (70%). Furthermore, the mean body mass index was 28.47 Ϯ 9.57 kg/m 2 , and the mean left ventricular ejection fraction (LVEF) was 39.05% Ϯ 0.15%. Of note, five patients (50%) had an LVEF r 30%, and one patient had a left ventricular assist device implanted for end-stage left-heart failure.
Intra-Procedure Safety and Efficacy Outcomes
S-ICD implantation was accomplished successfully using solely MAC without any major adverse events. Specifically, there were no instances of refractory hypotension, significant bradycardia, or respiratory compromise requiring endotracheal intubation. Furthermore, the implanting conditions provided by MAC were adequate and facilitated timely S-ICD implantation, without any significant intra-procedure or post-procedure patient discomfort. The mean intra-procedure duration was 131.40 Ϯ 26.05 minutes.
Hemodynamic Impact of MAC
The use of MAC was not associated with significant hemodynamic changes, with minimal requirement for pharmacologic support and no need for invasive blood pressure monitoring. Among all patients, the mean baseline MAP was 92.8 mmHg (95% CI: 82.77-102.83), and the mean end-procedure MAP was 88 mmHg (95% CI: 81.00-95.00; p ¼ 0.26 compared to baseline). When compared to baseline and end-procedure, the mean lowest intra-procedure MAP was significantly lower (67.4 mmHg, 95% CI: 59.08-75.72; p ¼ 0.0001). The intra-procedure variations in MAP are demonstrated in Figure 1A . Furthermore, only two patients (20%) received vasopressors/inotropes to maintain a MAP Z 60 mmHg. Patient A received 5 μg of epinephrine, 10 mg of ephedrine, and 15 mg of ephedrine at separate time points for corresponding MAPs of 60 mmHg, 60 mmHg, and 55 mmHg, respectively. Patient B received 100 μg of phenylephrine for an MAP of 60 mmHg.
With respect to HR, there was no need for chronotropic therapy. The mean baseline HR was 65.70 bpm (95% CI: 57.30-74.10), and the mean end-procedure HR was 70.10 bpm (95% CI: 62.40-77.80; p ¼ 0.28 compared to baseline). When compared to baseline and end-procedure, the mean lowest intra-procedure HR was significantly lower (55.80 bpm, 95% CI: 50.03-61.57; p o 0.001). The intra-procedure variations in HR are demonstrated in Figure 1B .
Defibrillation Threshold Testing Hemodynamics
In the seven patients who underwent DFT testing, VF was induced a total of eight times (mean of 1.14 Ϯ 0.35 VF inductions per patient). A total of eight defibrillation shock therapies were delivered, seven via the S-ICD, and one from an external biphasic defibrillator. For the first DFT test, the mean MAP pre-DFT (5 minutes before DFT test) was 70.71 mmHg (95% CI: 64.61-76.82), the mean MAP at DFT (immediately after VF shock conversion) was 89.14 mmHg (95% CI: 78.67-99.61), and the mean MAP post-DFT (5 minutes after DFT test) was 85.71 mmHg (95% CI: 78.92-92.50). The changes in MAP during DFT are depicted in Figure 2A . The mean HR pre-DFT was 67 bpm (95% CI: 53.09-80.91), the mean HR at DFT was 72.57 bpm (95% CI: 54.80-90.34), and the mean HR post-DFT was 71.57 bpm (95% CI: 57.98-85. 16 ). The changes in HR during DFT are shown in Figure 2B . Following DFT testing, there were increases in both MAP and HR in each of the 7 patients, and there was no need for pharmacologic support.
Post-Procedure
All the study patients had a rapid recovery in the postanesthesia care unit without any adverse events. The highest pain score was "mild."
DISCUSSION
Main Findings
This study represented the first series describing the use of MAC in high-risk patients undergoing S-ICD implantation. The main findings of this study were: (1) S-ICD implantation and DFT testing could be accomplished safely using MAC with the guidance of an anesthesiologist and an electrophysiologist without any major hemodynamic deterioration or respiratory compromise; and (2) MAC was efficacious for S-ICD implantation.
Hemodynamics
Considering that the occurrence of hypotension (MAP o 60 mmHg) during non-cardiac surgery has been associated with significant morbidity and mortality, the primary anesthetic concern during S-ICD implantation and DFT testing is the maintenance of adequate MAP and HR. 7, 9, 13, 14 Furthermore, in comparison to MAC, the degree of hypotension has been reported higher using GA with volatile anesthetics. 7 In this series, despite a patient population with extensive cardiovascular disease (5 patients had an LVEF o 30% and 7 patients had an ASA score of IV), only 1 patient developed important hypotension (MAP o 60 mmHg) that was treated with a single dose of ephedrine, 15 mg. Also, DFT testing was associated with increases in MAP and HR, and no patient developed hypotension in the post-anesthesia care unit.
In the authors' prior publication, the use of GA was associated with significant hypotension in more than 50% of the patients. 6 Possible reasons for this greater incidence of 
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hypotension compared to the current study were that the number of delivered shocks was greater (3 Ϯ 2.9 shocks per patient), and the intra-procedure duration was longer (186.2 Ϯ 54.1 minutes), as well as the negative impact of volatile anesthetics on myocardial contractility and vasomotor tone. 6,7
Anesthesia
As described by the ASA, MAC represents a continuum of anesthesia care, from the awake state to potential GA without intubation. 15, 16 As such, during S-ICD implantation and DFT testing with MAC, the depth of anesthesia was adjusted to ensure optimal implanting conditions for the electrophysiologist (ie, avoidance of patient movement or patient discomfort) and the prevention of patient awareness, especially during DFT testing). Considering that the pulse generator pocket was created after the infiltration of local anesthesia, this period required mild-tomoderate sedation. Tunneling of the defibrillator lead (the most stimulating aspect of S-ICD implantation) required deep sedation due to the inability to infiltrate local anesthesia along the entire path of the lead. Furthermore, DFT testing also required deep sedation to prevent patient awareness. Notably, all the study patients denied intraoperative awareness post-procedure, and tolerated device implantation and DFT testing well.
A propofol infusion is ideal for this type of procedure, in which the bulk of the procedure requires mild-to-moderate sedation and, only when deeper sedation is required for the total 1-to 2-minute tunneling procedures and DFT testing, then the propofol infusion is increased briefly. Additionally, the rapid onset and offset of propofol sedation enable the maintenance of spontaneous respirations during the procedure, without the need for endotracheal intubation. 10,11
Limitations
This was a single-center observational study with a small sample size (n = 10) and without a control group. As such, the generalizability of the authors' results is limited. However, the data presented were collected prospectively and recorded automatically in the electronic medical record, thus reflecting accurate outcomes. Although the protocol for MAC was not standardized, the care provided was consistent with expected care with MAC as directed by experienced anesthesiologists and tailored to the patient characteristics.
CONCLUSIONS
To date, studies supported GA as the anesthetic of choice to manage patients undergoing S-ICD implantation. However, considering the novel nature of the S-ICD, the best anesthetic choice remains undefined. This study was the first series to report outcomes using MAC for S-ICD procedures. Among a heterogeneous patient population with major cardiovascular disease and other comorbidities undergoing S-ICD implantation and DFT testing, MAC, provided by an experienced anesthesiologist, was demonstrated to be safe and efficacious. There were no important reductions in MAP or HR and no requirements for intubation, as well as excellent management of procedure pain. These results suggested that MAC can be considered as an alternative to GA when applied to carefully selected patients who are free from obesity, gastroesophageal reflux disease, non-reassuring airway status, sleep apnea, unstable baseline hemodynamics, and pulmonary hypertension. Ongoing randomized studies will provide further insight into outcomes using MAC in comparison to GA for S-ICD procedures.
